How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to the consensus estimate of $4.10 million. PLx Pharma had a negative trailing twelve-month return on equity of 291.11% and a negative net margin of 606.91%. PLx Pharma's revenue for the quarter was up 560.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

What other stocks do shareholders of PLx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET) , Fulcrum Therapeutics (FULC) , CymaBay Therapeutics (CBAY) , VIVUS (VVUS) , Paratek Pharmaceuticals (PRTK) , Sorrento Therapeutics (SRNE) , Cornerstone Strategic Value Fund (CLM) , NewLink Genetics (NLNK) , SCYNEXIS (SCYX) and Viking Therapeutics (VKTX) .

When did PLx Pharma IPO?

PLx Pharma (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

NASDAQ:PLXP

PLx Pharma (PLXP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PLXP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 3,000 shs
Average Volume: 12.96 million shs
Market Capitalization: $603,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get PLx Pharma alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About PLx Pharma Stock (NASDAQ:PLXP)

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

PLXP Stock News Headlines

January 30, 2024 | investing.com

Protalix Biotherapeutics Inc (PLX)

January 22, 2024 | morningstar.com

Vertex Pharmaceuticals Inc VRTX

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 23, 2023 | investing.com

Vietnam National Petroleum Group (PLX)

August 21, 2023 | uk.investing.com

PLx Pharma Inc (PLXPQ)

April 21, 2023 | seekingalpha.com

PLXPQ PLx Pharma Inc.

April 13, 2023 | marketwatch.com

PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assets

April 12, 2023 | msn.com

Why PLx Pharma Shares Are Nosediving Today

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2023 | msn.com

Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

April 11, 2023 | msn.com

Why PLx Pharma Shares Are Down Over 40% Tuesday

April 11, 2023 | finance.yahoo.com

PLx Pharma Inc. Receives Nasdaq Delisting Notice

April 11, 2023 | msn.com

Short Volatility Alert: Plx Pharma Inc

December 22, 2022 | msn.com

PLx Pharma's Return On Capital Employed Insights

November 11, 2022 | seekingalpha.com

PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript

November 11, 2022 | seekingalpha.com

PLx Pharma down after Q3 revenue fell 94% Y/Y

November 10, 2022 | finance.yahoo.com

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

November 10, 2022 | finance.yahoo.com

PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates

November 10, 2022 | msn.com

Earnings Preview: PLx Pharma

October 26, 2022 | finance.yahoo.com

PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

September 12, 2022 | finance.yahoo.com

Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels

September 5, 2022 | finance.yahoo.com

PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k

August 20, 2022 | finance.yahoo.com

PLXP Aug 2022 5.000 call

August 15, 2022 | seekingalpha.com

PLx Pharma downgraded at Oppenheimer after Q2 miss

August 12, 2022 | marketwatch.com

PLx Pharma to Explore Strategic Alternatives, Reduces Team

August 12, 2022 | apnews.com

Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg

August 12, 2022 | markets.businessinsider.com

PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%

See More Headlines

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PLXP
CUSIP: N/A
CIK: 1497504
Web: www.plxpharma.com
Phone: (973) 409-6541
Fax: 713-842-3052
Employees: 16
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): ($1.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,130,000.00
Net Margins: -606.91%
Pretax Margin: -606.91%
Return on Equity: -291.11%
Return on Assets: -119.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.79
Quick Ratio: 4.28

Sales & Book Value

Annual Sales: $4.54 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 29,138,000
Free Float: 26,530,000
Market Cap: $603,000.00
Optionable: Not Optionable
Beta: 3.79

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Natasha Giordano
President, Chief Executive Officer & Director
Rita M. O'Connor
CFO, Head-Manufacturing & Supply Chain
Mayme Lou Roettig
Executive Medical Director
Thomas L. Long
VP-Manufacturing & Technical Operations
Lawrence R. Perkins
Chief Restructuring Officer

Key Competitors

View All Competitors

PLXP Stock Analysis - Frequently Asked Questions

How were PLx Pharma's earnings last quarter?: PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. The biotechnology company earned $6.60 million during the quarter, compared to the consensus estimate of $4.10 million. PLx Pharma had a negative trailing twelve-month return on equity of 291.11% and a negative net margin of 606.91%. PLx Pharma's revenue for the quarter was up 560.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.40) earnings per share.
What other stocks do shareholders of PLx Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).
When did PLx Pharma IPO?: PLx Pharma (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

This page (NASDAQ:PLXP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PLx Pharma (PLXP) Stock Price, News & Analysis

About PLx Pharma Stock (NASDAQ:PLXP)

PLXP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

PLXP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info